X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PIRAMAL ENTERPRISES ELDER PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -0.2 39.2 - View Chart
P/BV x 0.1 3.3 3.1% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PIRAMAL ENTERPRISES
Mar-17
ELDER PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3802,095 18.1%   
Low Rs1881,025 18.3%   
Sales per share (Unadj.) Rs491.2492.8 99.7%  
Earnings per share (Unadj.) Rs-3.272.6 -4.4%  
Cash flow per share (Unadj.) Rs14.494.7 15.2%  
Dividends per share (Unadj.) Rs021.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs376.5862.5 43.7%  
Shares outstanding (eoy) m20.54172.56 11.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.2 18.3%   
Avg P/E ratio x-89.321.5 -415.2%  
P/CF ratio (eoy) x19.716.5 119.6%  
Price / Book Value ratio x0.81.8 41.7%  
Dividend payout %028.9 0.0%   
Avg Mkt Cap Rs m5,833269,194 2.2%   
No. of employees `000NA4.0 0.0%   
Total wages/salary Rs m2,17917,939 12.1%   
Avg. sales/employee Rs ThNM21,190.3-  
Avg. wages/employee Rs ThNM4,470.1-  
Avg. net profit/employee Rs ThNM3,120.0-  
INCOME DATA
Net Sales Rs m10,08985,037 11.9%  
Other income Rs m2572,338 11.0%   
Total revenues Rs m10,34687,374 11.8%   
Gross profit Rs m-79234,991 -2.3%  
Depreciation Rs m3613,817 9.5%   
Interest Rs m2,75620,310 13.6%   
Profit before tax Rs m-3,65313,202 -27.7%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713-100 -3,731.4%   
Tax Rs m1252,281 5.5%   
Profit after tax Rs m-6512,520 -0.5%  
Gross profit margin %-7.841.1 -19.1%  
Effective tax rate %-3.417.3 -19.8%   
Net profit margin %-0.614.7 -4.4%  
BALANCE SHEET DATA
Current assets Rs m9,24087,590 10.5%   
Current liabilities Rs m9,998185,578 5.4%   
Net working cap to sales %-7.5-115.2 6.5%  
Current ratio x0.90.5 195.8%  
Inventory Days Days4631 149.2%  
Debtors Days Days6048 126.1%  
Net fixed assets Rs m10,124108,523 9.3%   
Share capital Rs m206345 59.6%   
"Free" reserves Rs m5,582148,481 3.8%   
Net worth Rs m7,734148,826 5.2%   
Long term debt Rs m4,889144,957 3.4%   
Total assets Rs m22,882482,394 4.7%  
Interest coverage x-0.31.7 -19.7%   
Debt to equity ratio x0.61.0 64.9%  
Sales to assets ratio x0.40.2 250.1%   
Return on assets %11.86.8 172.8%  
Return on equity %-0.88.4 -10.0%  
Return on capital %22.312.0 186.7%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30715,001 2.0%   
Fx outflow Rs m1255,150 2.4%   
Net fx Rs m1819,851 1.8%   
CASH FLOW
From Operations Rs m11,754-100,393 -11.7%  
From Investments Rs m-561-24,202 2.3%  
From Financial Activity Rs m-6,762135,705 -5.0%  
Net Cashflow Rs m4,43211,110 39.9%  

Share Holding

Indian Promoters % 39.6 52.9 74.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 4.0 187.5%  
FIIs % 16.8 26.6 63.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 16.5 218.8%  
Shareholders   16,479 93,274 17.7%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Market at Record Highs; Strong ITC & RIL Performance & Other Top Cues to Sway the Market Today(Pre-Open)

Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services. At the closing bell last week.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - DR. DATSONS LABS COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS